NCT03325790View on ClinicalTrials.gov

SPI-1005 for the Treatment of Patients With Meniere's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

149

Participants

Timeline

Start Date

September 28, 2017

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions

Meniere's Disease

Interventions

DRUG

200mg SPI-1005 BID

Active: low dose

DRUG

400mg SPI-1005 BID

Active: high dose

OTHER

Placebo

Placebo Comparator

Trial Locations (13)

10017

ENT and Allergy Associates, LLP, New York

19144

TJU, Philadelphia

20057

Georgetown University, Washington D.C.

28210

CEENTA, Charlotte

29425

MUSC, Charleston

33146

UMiami, Miami

40207

Advanced ENT & Allergy, Louisville

66160

KUMC, Kansas City

75390

UT Southwestern, Dallas

92093

UCSD, San Diego

93720

Ccent/Cccr, Fresno

94115

UCSF, San Francisco

98104

Northwest Ear, Inc., Seattle

All Listed Sponsors

lead

Sound Pharmaceuticals, Incorporated

INDUSTRY

NCT03325790 - SPI-1005 for the Treatment of Patients With Meniere's Disease | Biotech Hunter | Biotech Hunter